Braveheart Bio (BRVE) news
Recent news
Braveheart Bio, Inc.: Stifel initiates coverage with buy rating; target price $45
Stifel Nicolaus has initiated coverage of Braveheart Bio, Inc. (Nasdaq: BRVE) with a "Buy" rating and a target price of $45 per share. Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious…
AInvest Wire · 8h agoBraveheart Bio, Inc.: TD Cowen initiates coverage with buy rating
AInvest Wire · 9h agoBraveheart Bio opens at $30.20, IPO at $18
Braveheart Bio (BRVE), a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy and other cardiovascular diseases, saw its shares open at $30.20 on the Nasdaq Global Market on August 6, 2026, significantly above its IPO price of $18.00 . The company…
AInvest Wire · Aug 6, 2026Braveheart Bio shares indicated to open at $25, IPO price $18
AInvest Wire · Aug 6, 2026Braveheart said to allocate zero shares to 70% of IPO orders
Braveheart Bio’s IPO has drawn attention due to its allocation strategy, which reportedly reserved zero shares for 70% of IPO orders. The company is offering 18.75 million shares at a price range of $15–$17 per share, with purchase up to 2.8125 million additional shares. Goldman Sachs & Co. LLC and…
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.